Marker Therapeutics (NASDAQ:MRKR) Upgraded by Brookline Capital Management to “Strong-Buy” Rating

Brookline Capital Management upgraded shares of Marker Therapeutics (NASDAQ:MRKR) to a strong-buy rating in a research note released on Monday,Zacks.com reports.

Separately, LADENBURG THALM/SH SH upped their target price on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a report on Monday, October 21st.

Marker Therapeutics Trading Up 2.6 %

Shares of NASDAQ MRKR opened at $1.59 on Monday. Marker Therapeutics has a 52-week low of $1.48 and a 52-week high of $5.99. The company’s 50-day simple moving average is $2.88 and its 200-day simple moving average is $3.24.

Insider Activity at Marker Therapeutics

In other Marker Therapeutics news, Director Steve Elms purchased 11,085 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was acquired at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the completion of the purchase, the director now directly owns 325,370 shares in the company, valued at approximately $1,041,184. The trade was a 3.53 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Enterprise Associates 16 New bought 554,250 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average cost of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the purchase, the insider now directly owns 1,625,678 shares in the company, valued at $5,202,169.60. This represents a 51.73 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 17.35% of the stock is owned by insiders.

Institutional Trading of Marker Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. LPL Financial LLC purchased a new position in shares of Marker Therapeutics during the fourth quarter worth about $248,000. Invst LLC purchased a new stake in Marker Therapeutics during the 3rd quarter valued at approximately $56,000. Finally, Aisling Capital Management LP lifted its position in Marker Therapeutics by 3.5% during the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock worth $1,012,000 after acquiring an additional 11,084 shares during the period. Institutional investors and hedge funds own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.